Stay updated with breaking news from Rad Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IAM is a unique and timely intelligence service that treats IP as a business asset and tool rather than simply as a legal right, informing boardrooms worldwide.
Whistleblower protections are central to the suite of SOX oversight reforms, encouraging and protecting individual reports of potentially fraudulent conduct.
On July 13, 2022, the United States Court of Appeals for the First Circuit ruled that the whistleblower protections contained in Section 806 of the Sarbanes-Oxley Act (SOX) do not apply...
10X Genomics challenged claims in Bio-Rad’s U.S. Pat. No. 9,562,837 and 9,896,722. The PTAB issued four mixed Final Written Decisions in 10X Genomics Inc. v. Bio-Rad Labs., Inc., IPR2020-00086, -00087, -00088, and -00089, finding most claims unpatentable but allowing a few to survive.
In Vectura, the Federal Circuit recently reiterated that the entire market value of an accused multicomponent product may serve as the royalty base if the patent damages analysis is built on sufficiently comparable licenses. Vectura Limited v. Glaxosmithkline LLC, 981 F.3d 1030, 1040-1042 (Fed. Cir. 2020). Pursuit of the entire market value of a multicomponent product ordinarily requires the patentee to demonstrate that the infringing feature drives customer demand for the product. Virnetx, Inc. v. Cisco Sys., Inc., 767 F.3d 1308, 1326 (Fed. Cir. 2014). Without such evidence, the patentee ...